Therapeutic area intelligence for Burkitt Lymphoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

DA-EPOCH-R →

Assets

CHAF1A →

Epcoritamab →

Recent signals(2)

ClinicalAugust 2, 2026

CHAF1A Emerges as Biomarker and Target in Burkitt Lymphoma

CHAF1A has been identified as a candidate biomarker and potential therapeutic target in Burkitt lymphoma through bioinformatics and histopathological analysis.

ClinicalJune 24, 2026

Epcoritamab Shows Promise in High-risk Burkitt Lymphoma with DA-EPOCH-R in Phase II Trial

The phase II BEDROCK study is evaluating the efficacy of epcoritamab combined with DA-EPOCH-R in high-risk Burkitt lymphoma patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Burkitt Lymphoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.